Pre-Made Davoceticept Biosimilar, Fusion Protein targeting CD274/PD-L1 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting B7-H/B7H1/PDCD1L1/PDCD1LG1 for drug discovery and mechanism of action (MOA) research

Pre-Made Davoceticept Biosimilar, Fusion Protein targeting CD274/PD-L1 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting B7-H/B7H1/PDCD1L1/PDCD1LG1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Davoceticept contains a variant CD80 domain (vIgD™) fused to an “effectorless” IgG Fc. Davoceticept is used to bind PD-L1 as well as CD28 and CTLA-4. Localized to the tumor by high-affinity binding to PD-L1, davoceticept activates T cells by clustering and agonism of CD28 only in the presence of PD-L1. Additionally, davoceticept binds CTLA-4 expressed on T cells and blocks CTLA4-CD80/CD86 interactions, further potentiating T cell activity.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-797-1mg	1mg	3090
GMP-Bios-INN-797-10mg	10mg	Inquiry
GMP-Bios-INN-797-100mg	100mg	Inquiry
GMP-Bios-INN-797-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Davoceticept Biosimilar, Fusion Protein targeting CD274/PD-L1 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting B7-H/B7H1/PDCD1L1/PDCD1LG1
INN Name	Davoceticept
Target	CD274/PD-L1
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [CD80 (B7- 1, CD28LG1) fragment (1-107)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [CD80 (B7- 1, CD28LG1) fragment (1-107)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Alpine Immune Sciences (Seattle WA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0